Skip to content

US · LNTH · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Lantheus Holdings, Inc. (LNTH) intrinsic value and stock valuation

$102.10as of 2026-11-21 · Mkt cap 6.61B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lantheus Holdings, Inc. DCF and intrinsic value

InvestorsCraft values LNTH with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from LNTH’s statements →

Lantheus Holdings, Inc. Graham Number

Graham Number: $35.46d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Bedford, MA 01730 lantheus.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.54B+35.3% 5y CAGRd
20112025
Net income
$233.6M
20112025
Free cash flow
$354.1M+146.1% 5y CAGRd
20112025
Total equity
$1.09B+16.2% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.54B$1.53B$1.3B$935.1M$425.2M
Operating income$310.8M$457M$364.6M$36.2M-$-60.83M
Net income$233.6M$312.4M$326.7M$28.1M-$-71.28M
EPSd$3.41M$4.36M$4.65M$397.2K-$-1.06M
Operating cash flow$390.1M$544.8M$305.3M$281.8M$53.9M
Capital expenditure-$-36.09M-$-51.62M-$-46.55M-$-18.35M-$-12.14M
Free cash flow$354.1M$493.1M$258.7M$263.4M$41.8M
Total assets$2.23B$1.98B$1.65B$1.32B$863.8M
Total debt$619.4M$619.4M$617M$583.5M$191.3M
Net debt$260.3M-$-293.38M-$-96.71M$167.9M$92.8M
Total equity$1.09B$1.09B$815.9M$447.2M$464.4M
Cash and short-term investments$359.1M$912.8M$713.7M$415.7M$98.5M
Income statement
20252024202320222021
Revenue$1.54B$1.53B$1.3B$935.1M$425.2M
Cost of revenue$599.7M$545.6M$586.9M$353.4M$237.5M
Gross profit$942M$988.3M$709.5M$581.7M$187.7M
Research and development expenses$177.3M$168.1M$77.7M$311.7M$45M
Selling, general and administrative expenses$453.8M$371.6M$267.2M$233.8M$218.8M
Other expenses$0.00-$-8.41M$0.00$0.00-$-15.26M
Operating expenses$631.1M$531.3M$344.9M$545.5M$248.5M
Cost and expenses$1.23B$1.08B$931.8M$898.9M$486M
Interest income$23.4M$36.8M$19.6M$2.61M$40K
Interest expense$19.8M$19.7M$20M$7.18M$7.75M
Depreciation and amortization$70.1M$64.6M$60M$47.9M$42.3M
Ebitda$403.6M$515.3M$491M$81.8M-$-25M
Operating income$310.8M$457M$364.6M$36.2M-$-60.83M
Total other income/expenses, net$2.96M-$-26M$46.3M-$-9.48M-$-14.21M
Income before tax$313.8M$431M$410.9M$26.7M-$-75.04M
Income tax expense$80.2M$118.5M$84.3M-$-1.35M-$-3.76M
Net income$233.6M$312.4M$326.7M$28.1M-$-71.28M
Weighted average shares outstanding$67.5M$69.2M$68.3M$68.5M$67.5M
Weighted average diluted shares outstanding$68.4M$71.7M$70.2M$70.7M$67.5M
Balance sheet
20252024202320222021
Cash and short-term investments$359.1M$912.8M$713.7M$415.7M$98.5M
Net receivables$358.6M$321.3M$284.3M$213.4M$89.3M
Inventory$64.7M$68M$64M$35.5M$35.1M
Total current assets$900M$1.33B$1.09B$677.6M$235.8M
Property, plant and equipment, net$163.7M$212.9M$192M$141.2M$125.6M
Goodwill and intangible assets$962.3M$223M$213.2M$376.5M$409.7M
Long-term investments$42.2M$39.5M$0.00$0.00$0.00
Total non-current assets$1.33B$653.7M$565.3M$643.6M$628M
Total assets$2.23B$1.98B$1.65B$1.32B$863.8M
Accounts payable$42.9M$34.6M$41.2M$20.6M$20.8M
Short-term debt$740K$970K$820K$350K$11.6M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$333.4M$240.5M$187.4M$247.7M$90.5M
Long-term debt$618.7M$618.5M$616.1M$583.2M$179.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$804.2M$651.8M$647.9M$626.4M$308.9M
Capital lease obligations$50M$53.2M$54.5M$25.4M$16.6M
Total liabilities$1.14B$892.3M$835.3M$874.1M$399.4M
Common stock$720K$710K$700K$690K$680K
Retained earnings$679.5M$445.9M$133.5M-$-193.16M-$-221.22M
Accumulated other comprehensive income (loss)-$-1.31M-$-1.61M-$-1.04M-$-1.26M-$-480K
Total equity$1.09B$1.09B$815.9M$447.2M$464.4M
Total investments$42.2M$39.5M$0.00$0.00$0.00
Total debt$619.4M$619.4M$617M$583.5M$191.3M
Net debt$260.3M-$-293.38M-$-96.71M$167.9M$92.8M
Cash flow statement
20252024202320222021
Net income$233.6M$312.4M$326.7M$28.1M-$-71.28M
Depreciation and amortization$70.1M$64.6M$60M$47.9M$42.3M
Stock-based compensation$0.00$76.4M$50.5M$29.3M$15.9M
Change in working capital-$-44.23M$2.05M-$-171.2M-$-75.06M-$-15.15M
Accounts receivable-$-17.89M-$-37.69M-$-68.64M-$-128.46M-$-33.1M
Inventory-$-9.37M-$-2.67M-$-36.22M-$-7.51M-$-3.55M
Accounts payable-$-2.49M-$-8.8M$17.2M$300K$5.42M
Net cash provided by operating activities$390.1M$544.8M$305.3M$281.8M$53.9M
Investments in property, plant and equipment-$-41.5M-$-79.62M-$-46.55M-$-18.35M-$-12.14M
Acquisitions, net-$-575.67M-$-80.91M$0.00$0.00$0.00
Net cash used for investing activities-$-627.17M-$-226.01M$5.94M-$-276.55M$3.68M
Common stock issued$10.9M$3.45M$1.93M$1.38M$770K
Common stock repurchased-$-300.02M-$-100M$0.00-$-75M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-316.58M-$-118.54M-$-13.06M$311.7M-$-39.33M
Net change in cash-$-553.66M$199.2M$298M$316.6M$18M
Cash at end of period$360.8M$914.5M$715.3M$417.2M$100.7M
Operating cash flow$390.1M$544.8M$305.3M$281.8M$53.9M
Capital expenditure-$-36.09M-$-51.62M-$-46.55M-$-18.35M-$-12.14M
Free cash flow$354.1M$493.1M$258.7M$263.4M$41.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lantheus Holdings, Inc.

        Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.

        CEO
        Mary Anne Heino
        Employees
        1.19K
        Beta
        -0.06

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Lantheus Holdings, Inc. (LNTH)?

        Lantheus Holdings, Inc. (LNTH) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LNTH undervalued?

        LNTH trades at a price of $102.10 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.